News
TNXP
1.150
0.00%
0.000
Tonix Pharmaceuticals Announces Presentation Of Licensed Antiviral Drug Technology At The 2nd Wnt & β-catenin Targeted Drug Development Conference
Benzinga · 1d ago
BRIEF-Tonix Pharmaceuticals Ends Year With About $120.2 Mln In Cash, Cash Equivalents
Reuters · 3d ago
Tonix CEO Seth Lederman Calls For New Class Of Covid-19 Pre-Exposure And Therapeutic Antibodies For High-Risk Populations
Benzinga · 4d ago
Tonix Pharmaceuticals Announces Publication Of Paper In Antiviral Research Highlighting The Company's Development Of Monoclonal Antibody Therapeutics For Monkeypox And Smallpox
Benzinga · 4d ago
BRIEF-Tonix Pharmaceuticals Publishes Paper In Antiviral Research, Highlights Development Of Monoclonal Antibody Therapeutics
Reuters · 4d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 5d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 01/19 17:30
Alliance Global Partners Reiterates Buy on Tonix Pharmaceuticals, Maintains $6.5 Price Target
Benzinga · 01/12 11:38
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 01/11 17:30
Lipella, Inotiv top healthcare gainers; Tonix, Prenetics among losers
Seeking Alpha · 01/11 15:00
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga · 01/06 18:16
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 01/06 17:30
BRIEF-Tonix Pharmaceuticals Enrolls First 50% Of Participants In Phase 3 Study Of TNX-102 SL
Reuters · 12/19/2022 12:23
Tonix Pharmaceuticals Achieves Enrollment Of First 50% Of Participants In The RESILIENT Study, A Potentially Pivotal Confirmatory Phase 3 Study Of TNX-102 SL For The Management Of Fibromyalgia
Benzinga · 12/19/2022 12:03
Tonix Pharmaceuticals Enrolls Half of Patients in Phase 3 Study of TNX-102 SL to Manage Fibromyalgia
Tonix Pharmaceuticals Enrolls Half of Patients in Phase 3 Study of TNX-102 SL to Manage Fibromyalgia
MT Newswires · 12/19/2022 08:56
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday's Mid-Day Session
Benzinga · 12/12/2022 18:05
Crude Oil Rises Sharply; Adicet Bio Shares Plunge
Benzinga · 12/12/2022 17:15
Why Is Reborn Coffee (REBN) Stock Up 34% Today?
Investor Place · 12/12/2022 17:14
Why Is Harpoon Therapeutics (HARP) Stock Up 100%+ Today?
Investor Place · 12/12/2022 16:51
Why Is Tonix Pharmaceuticals (TNXP) Stock Up 40% Today?
Investor Place · 12/12/2022 16:38
More
Webull provides a variety of real-time TNXP stock news. You can receive the latest news about Tonix Pharmaceut through multiple platforms. This information may help you make smarter investment decisions.
About TNXP
Tonix Pharmaceuticals Holding Corp. (Tonix) is a clinical-stage biopharmaceutical company. It is focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonixs portfolio is primarily composed of immunology and central nervous system (CNS) and infectious disease product candidates. Its immunology portfolio includes biologics to address organ transplant rejection, autoimmune diseases, and cancer. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Its infectious disease portfolio of product candidates includes vaccines to prevent COVID-19, an antiviral to treat COVID-19, and treatment for long COVID. The infectious disease portfolio also includes a vaccine in development to prevent smallpox and monkeypox. Its product candidates include TNX-1500, TNX-1300, TNX-102 SL, TNX-102 SL, TNX-102 SL,TNX-1900,TNX-601 CR, and TNX-1900.